Poll: Will You Recommend Triptorelin to Reproductive-Age Patients With Breast Cancer?

Article

Researchers from Italy have found that premenopausal breast cancer patients treated with triptorelin and chemotherapy were less likely to experience early menopause and were more likely to resume menses than patients who received chemotherapy alone.

 

Researchers from Italy have found that premenopausal breast cancer patients treated with triptorelin and chemotherapy were less likely to experience early menopause and were more likely to resume menses than patients who received chemotherapy alone. The study enrolled 281 premenopausal women across 16 sites; patients in the triptorelin plus chemotherapy group had 3.75 mg doses administered intramuscularly at least 1 week prior to chemotherapy initiation and then every 4 weeks during chemotherapy.

Add your thoughts to our poll.

Related Videos
Fezolinetant effective against vasomotor symptoms | Image Credit: med.unc.edu
Gloria Richard-Davis MD, MBA, NCMP, FACOG
Beth Garner, MD, MPH
© 2023 MJH Life Sciences

All rights reserved.